Century Therapeutics (NASDAQ:IPSC) Upgraded at Wall Street Zen

Century Therapeutics (NASDAQ:IPSC) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Chardan Capital reduced their price target on Century Therapeutics from $7.00 to $6.00 and set a “buy” rating for the company in a report on Friday, May 16th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $3.75.

Century Therapeutics Price Performance

Shares of NASDAQ:IPSC opened at $0.50 on Friday. Century Therapeutics has a 1-year low of $0.34 and a 1-year high of $1.86. The business has a fifty day moving average price of $0.55 and a 200-day moving average price of $0.56. The company has a market capitalization of $43.60 million, a PE ratio of -1.74 and a beta of 1.78.

Century Therapeutics (NASDAQ:IPSC) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.38) earnings per share for the quarter, meeting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. On average, sell-side analysts anticipate that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Millennium Management LLC grew its stake in shares of Century Therapeutics by 1,041.8% during the 4th quarter. Millennium Management LLC now owns 1,607,174 shares of the company’s stock valued at $1,623,000 after acquiring an additional 1,466,415 shares during the period. Jane Street Group LLC bought a new position in shares of Century Therapeutics during the 2nd quarter valued at approximately $248,000. Acadian Asset Management LLC grew its stake in shares of Century Therapeutics by 101.2% during the 1st quarter. Acadian Asset Management LLC now owns 284,229 shares of the company’s stock valued at $133,000 after acquiring an additional 142,953 shares during the period. Deutsche Bank AG grew its stake in shares of Century Therapeutics by 890.7% during the 4th quarter. Deutsche Bank AG now owns 193,368 shares of the company’s stock valued at $195,000 after acquiring an additional 173,849 shares during the period. Finally, Goldman Sachs Group Inc. grew its stake in shares of Century Therapeutics by 26.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 179,635 shares of the company’s stock valued at $86,000 after acquiring an additional 38,052 shares during the period. 50.20% of the stock is currently owned by institutional investors.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.